Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.

× No keyword cloud information.

6 in total

1. Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma.

Authors: Terence T Sio; James A Martenson; Michael G Haddock; Paul J Novotny; Gregory J Gores; Steven R Alberts; Robert C Miller; Julie K Heimbach; Charles B Rosen
Journal: Am J Clin Oncol Date: 2016-06 Impact factor: 2.339

2. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.

Authors: Siyuan Dong; Xiaohan Qu; Wenya Li; Xinwen Zhong; Peiwen Li; Shize Yang; Xitao Chen; Mingrui Shao; Lin Zhang
Journal: J Hematol Oncol Date: 2015-04-29 Impact factor: 17.388

3. Overexpression of deubiquitinating enzyme USP28 promoted non-small cell lung cancer growth.

Authors: Lei Zhang; Biao Xu; Yong Qiang; Hairong Huang; Changtian Wang; Demin Li; Jianjun Qian
Journal: J Cell Mol Med Date: 2015-02-05 Impact factor: 5.310

Review 4. Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer.

Authors: Cristina Fernández-López; José Expósito-Hernández; Juan Pedro Arrebola-Moreno; Miguel Ángel Calleja-Hernández; Manuela Expósito-Ruíz; Rosa Guerrero-Tejada; Isabel Linares; José Cabeza-Barrera
Journal: Cancer Med Date: 2016-07-23 Impact factor: 4.452

5. Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations.

Authors: Ming-Szu Hung; Yu-Hung Fang; Yu-Ching Lin; Jr-Hau Lung; Meng-Jer Hsieh; Ying-Huang Tsai
Journal: Mol Clin Oncol Date: 2018-01-10

6. Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway.

Authors: Haoyue Hu; Yanyang Liu; Songtao Tan; Xiao Xiao Xie; Jun He; Feng Luo; Li Wang
Journal: Cancer Manag Res Date: 2020-05-19 Impact factor: 3.989

6 in total